Concenter BioPharma
Drugs for the Treatment and Prevention of Type 2 Diabetes
Company Overview
Snapshot
Founded in January 2014 by Dror Chevion and Prof. Mordechai (Mottie) Chevion, Concenter BioPharma operates with 1–10 employees. The company has raised $3.18 million across three funding rounds from two investors.
Business overview
Concenter BioPharma develops drugs for the treatment and prevention of Type 2 Diabetes. The company's core technology involves a platform of nonsteroidal chemical complexes derived from clinically approved components, designed to act as anti-inflammatory, iron-chelating, and antibiotic agents. These new chemical entities are intended to address the causes and symptoms of multiple indications, serving the pharmaceutical and biotechnology sectors within the Health Tech & Life Sciences industry.
Strategic signal
Concenter BioPharma is advancing its drug development efforts, evidenced by news in January 2020 highlighting a potential pill to address the root cause of diabetes. This indicates the company's focus on innovative therapeutic solutions and its commitment to tackling chronic diseases, signaling a long-term growth trajectory in the biopharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- When was Concenter BioPharma founded?
- Concenter BioPharma was founded in January 2014 by Dror Chevion and Prof. Mordechai (Mottie) Chevion.
- What is Concenter BioPharma's primary focus?
- Concenter BioPharma focuses on developing drugs for the treatment and prevention of type 2 diabetes, utilizing a platform of nonsteroidal chemical complexes.
- How much capital has Concenter BioPharma raised to date?
- Concenter BioPharma has raised a total of $3.18 million across three funding rounds.
- What was a key news highlight for Concenter BioPharma in January 2020?
- In January 2020, news highlighted Concenter BioPharma's development of a pill that could address the root cause of diabetes, indicating progress in their drug development efforts.